Clinical trial · NCT06930560 · RECRUITING · NA
HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
Sponsor: Johns Hopkins University
Summary
This randomized controlled trial study aims to evaluate a revised hearing care intervention for older adults with Alzheimer's Disease and Related Dementias (ADRD). The community-delivered hearing care intervention utilizes tailored strategies to assess impact on communication, neuropsychiatric symptoms (NPS), and care partner distress.
Interventions
- HEARS-NPS device · DEVICE
Tailored fitting and programming of a personal sound amplifier accompanied by an aural rehabilitation component.
- HEARS-NPS program · BEHAVIORAL
Tailored aural rehabilitation for participant and care partner.
Published eligibility criteria
Verbatim from the registry. Only the site can decide how these apply to a specific patient.
Inclusion Criteria: * Age 60 - 100 years old * English-speaking * Diagnosis of probable Alzheimer's Disease or other related dementia according to the core clinical criteria outlined in the National Institute on Aging (NIA) and Alzheimer's Association Guidelines * Speech frequency pure tone average (0.5- 4 kHz) \>25 db in the better-hearing ear; adult onset hearing loss * Availability of caregiver/study partner who is 18+ to participate in all study-related visits and who provides care supervision * Stable (for 2 weeks or longer) dosing of medication (e.g. antidepressants, antipsychotics) for neuropsychiatric symptoms Exclusion Criteria: * Current self-reported use of hearing aid or amplification device * Medical contraindication to use hearing aids ( e.g. draining ears) * Inability to participate in the 1-month follow up
Sites (1)
- Johns Hopkins Memory and Alzheimer's Treatment Center, Baltimore, Maryland · RECRUITING
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2025-11-24.